ATE247114T1 - Serotonergische modulatoren - Google Patents
Serotonergische modulatorenInfo
- Publication number
- ATE247114T1 ATE247114T1 AT95306253T AT95306253T ATE247114T1 AT E247114 T1 ATE247114 T1 AT E247114T1 AT 95306253 T AT95306253 T AT 95306253T AT 95306253 T AT95306253 T AT 95306253T AT E247114 T1 ATE247114 T1 AT E247114T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- substituted phenyl
- trifluoromethyl
- Prior art date
Links
- 230000000862 serotonergic effect Effects 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000001624 naphthyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Optical Integrated Circuits (AREA)
- Holo Graphy (AREA)
- Gyroscopes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9418326A GB9418326D0 (en) | 1994-09-12 | 1994-09-12 | Pharmaceutical compounds |
| GBGB9511166.2A GB9511166D0 (en) | 1995-06-02 | 1995-06-02 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE247114T1 true ATE247114T1 (de) | 2003-08-15 |
Family
ID=26305611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95306253T ATE247114T1 (de) | 1994-09-12 | 1995-09-07 | Serotonergische modulatoren |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0705832B1 (enEXAMPLES) |
| JP (1) | JPH0881464A (enEXAMPLES) |
| KR (1) | KR960010635A (enEXAMPLES) |
| CN (1) | CN1045602C (enEXAMPLES) |
| AT (1) | ATE247114T1 (enEXAMPLES) |
| AU (1) | AU698580B2 (enEXAMPLES) |
| CA (1) | CA2157998A1 (enEXAMPLES) |
| CZ (1) | CZ286565B6 (enEXAMPLES) |
| DE (1) | DE69531476T2 (enEXAMPLES) |
| ES (1) | ES2204932T3 (enEXAMPLES) |
| FI (1) | FI954243A7 (enEXAMPLES) |
| HU (1) | HU219491B (enEXAMPLES) |
| IL (1) | IL115236A (enEXAMPLES) |
| IN (1) | IN179550B (enEXAMPLES) |
| MY (1) | MY132009A (enEXAMPLES) |
| NO (1) | NO305174B1 (enEXAMPLES) |
| NZ (1) | NZ272961A (enEXAMPLES) |
| PE (1) | PE41796A1 (enEXAMPLES) |
| PH (1) | PH31631A (enEXAMPLES) |
| PL (1) | PL310373A1 (enEXAMPLES) |
| RU (1) | RU2146256C1 (enEXAMPLES) |
| TR (1) | TR199501114A2 (enEXAMPLES) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2308362A (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Ltd | Pharmaceutical indole derivatives |
| EP0905136A1 (en) * | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
| UA70334C2 (en) * | 1998-10-06 | 2004-10-15 | Janssen Pharmaceutica N V Jans | BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS |
| UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
| WO2002004409A2 (en) * | 2000-07-06 | 2002-01-17 | Us Gov Health & Human Serv | Tetrahydrobenzothiazole analogues as neuroprotective agents |
| DE10040016A1 (de) * | 2000-08-16 | 2002-02-28 | Boehringer Ingelheim Pharma | Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2002024662A1 (en) * | 2000-09-19 | 2002-03-28 | Boehringer Ingelheim Pharma Gmbh & Ko. Kg | New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| US6586435B2 (en) | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| JP5062938B2 (ja) * | 2000-09-19 | 2012-10-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | セロトニン受容体及びドーパミン受容体にアフィニティーを有する新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体 |
| US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| DE60206636T2 (de) * | 2001-08-08 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | THERAPEUTISCHE 1H-PYRIDO[4,3-b]INDOLE |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| RU2232578C1 (ru) * | 2003-04-10 | 2004-07-20 | Ахапкина Валентина Ивановна | Вещество, обладающее антидепрессивной активностью |
| WO2007014929A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of obesity |
| CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| MX2009001551A (es) | 2006-08-14 | 2009-02-20 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas. |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| BRPI0716436B8 (pt) | 2006-08-25 | 2021-05-25 | Boehringer Ingelheim Int | sistema de liberação controlada e método para fabricação do mesmo |
| UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
| KR20120093066A (ko) | 2009-05-29 | 2012-08-22 | 스미또모 가가꾸 가부시키가이샤 | 신경영양인자의 활성이 관여하는 질환의 치료 또는 예방제 |
| US10292971B2 (en) | 2015-10-01 | 2019-05-21 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs |
| EP3993785A4 (en) | 2019-07-07 | 2023-08-02 | Olema Pharmaceuticals, Inc. | ESTROGEN RECEPTOR ANTAGONIST SCHEMES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035369A (en) | 1975-10-08 | 1977-07-12 | Janssen Pharmaceutica N.V. | 1-Benzazolylalkyl-4-substituted-piperidines |
| IL69132A (en) * | 1982-07-14 | 1986-02-28 | Roussel Uclaf | Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them |
| US4636563A (en) * | 1985-09-16 | 1987-01-13 | American Home Products Corporation | Antipsychotic γ-carbolines |
| FR2661177A1 (fr) * | 1990-04-23 | 1991-10-25 | Rhone Poulenc Sante | Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant. |
-
1995
- 1995-09-07 ES ES95306253T patent/ES2204932T3/es not_active Expired - Lifetime
- 1995-09-07 EP EP95306253A patent/EP0705832B1/en not_active Expired - Lifetime
- 1995-09-07 DE DE69531476T patent/DE69531476T2/de not_active Expired - Fee Related
- 1995-09-07 AT AT95306253T patent/ATE247114T1/de not_active IP Right Cessation
- 1995-09-08 CZ CZ19952322A patent/CZ286565B6/cs not_active IP Right Cessation
- 1995-09-08 PH PH51266A patent/PH31631A/en unknown
- 1995-09-08 MY MYPI95002675A patent/MY132009A/en unknown
- 1995-09-08 HU HU9502631A patent/HU219491B/hu not_active IP Right Cessation
- 1995-09-08 NZ NZ272961A patent/NZ272961A/en unknown
- 1995-09-08 AU AU30497/95A patent/AU698580B2/en not_active Ceased
- 1995-09-11 KR KR1019950029475A patent/KR960010635A/ko not_active Ceased
- 1995-09-11 IN IN1079CA1995 patent/IN179550B/en unknown
- 1995-09-11 PL PL95310373A patent/PL310373A1/xx unknown
- 1995-09-11 RU RU95115522A patent/RU2146256C1/ru active
- 1995-09-11 CN CN95117133A patent/CN1045602C/zh not_active Expired - Fee Related
- 1995-09-11 IL IL115236A patent/IL115236A/en not_active IP Right Cessation
- 1995-09-11 JP JP7231873A patent/JPH0881464A/ja active Pending
- 1995-09-11 FI FI954243A patent/FI954243A7/fi unknown
- 1995-09-11 CA CA002157998A patent/CA2157998A1/en not_active Abandoned
- 1995-09-11 NO NO953575A patent/NO305174B1/no not_active IP Right Cessation
- 1995-09-12 PE PE1995278830A patent/PE41796A1/es not_active Application Discontinuation
- 1995-09-12 TR TR95/01114A patent/TR199501114A2/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69531476T2 (de) | 2004-06-09 |
| IL115236A (en) | 1998-06-15 |
| JPH0881464A (ja) | 1996-03-26 |
| AU3049795A (en) | 1996-03-28 |
| CN1129219A (zh) | 1996-08-21 |
| NO953575D0 (no) | 1995-09-11 |
| RU2146256C1 (ru) | 2000-03-10 |
| NO953575L (no) | 1996-03-13 |
| IL115236A0 (en) | 1995-12-31 |
| CA2157998A1 (en) | 1996-03-13 |
| HUT72593A (en) | 1996-05-28 |
| CZ232295A3 (en) | 1996-03-13 |
| HU9502631D0 (en) | 1995-11-28 |
| KR960010635A (ko) | 1996-04-20 |
| CN1045602C (zh) | 1999-10-13 |
| IN179550B (enEXAMPLES) | 1997-10-18 |
| NZ272961A (en) | 1998-02-26 |
| CZ286565B6 (cs) | 2000-05-17 |
| DE69531476D1 (de) | 2003-09-18 |
| AU698580B2 (en) | 1998-11-05 |
| EP0705832B1 (en) | 2003-08-13 |
| ES2204932T3 (es) | 2004-05-01 |
| NO305174B1 (no) | 1999-04-12 |
| EP0705832A1 (en) | 1996-04-10 |
| FI954243A7 (fi) | 1996-03-13 |
| FI954243A0 (fi) | 1995-09-11 |
| PE41796A1 (es) | 1996-10-21 |
| TR199501114A2 (tr) | 1996-10-21 |
| HU219491B (hu) | 2001-04-28 |
| PH31631A (en) | 1999-01-12 |
| MY132009A (en) | 2007-09-28 |
| PL310373A1 (en) | 1996-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE247114T1 (de) | Serotonergische modulatoren | |
| DE69634733D1 (de) | Benzamidoxime prodrugs und verwendung zur behandlung von pneumonie | |
| AU537414B2 (en) | Pyroglutamic acid derivatives | |
| DE19680619D2 (de) | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs | |
| AU3113793A (en) | Intermediates for preparing antipicornaviral pyridazinamines | |
| NO934718D0 (no) | Nye HIV protease inhibitorer | |
| DE69707372D1 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
| DE59607208D1 (de) | Verwendung eines Natrium- oder Lysiniumsalzes von Crotonsäureamidderivaten zur Herstellung eines Arzneimittels zur Behandlung von Krebserkrankungen | |
| FI914007A0 (fi) | 4-substituerade dihydropyrido (4,3-d) pyrimidiner som smaertslindrande och lokala inflammationshaemmande medel vid vaord av hudsjukdomar. | |
| DE3567647D1 (en) | N-(azolylcarbamoyl)-hydroxyl amines and fungicides containing them | |
| DK0387489T3 (da) | Anvendelse af 2,2,6,6-tetramethyl-4-aminopiperidinamider som fungicider | |
| NO304314B1 (no) | Cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler | |
| NZ316516A (en) | quinoline substituted carbamoyl carboxylic acid amides and medicaments | |
| ATE66221T1 (de) | Substituierte 5-amino-pyrazole und diese enthaltende fungizide. | |
| NO972943D0 (no) | 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse | |
| ATE31059T1 (de) | N-(arylpropyl)-azolylharnstoffe und diese enthaltende fungizide. | |
| ATE192141T1 (de) | Aromatische hydroxamsäure-verbindungen, ihre herstellung und verwendung | |
| DK347387A (da) | Amidderivater | |
| DE60005525D1 (de) | 2-aminotetraline zur behandlung von glaukom | |
| ATE186912T1 (de) | Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen | |
| NO972942L (no) | 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse | |
| ECSP951529A (es) | Compuestos farmaceuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |